Johnson & Johnson said clinical research indicates an enhanced dose that helps the level of antibody in people inject 9 times.

Temporary data from the first two-stage trials of increased doses showed that the second Johnson & Johnson (J & J) (J & J) nose helped 9 times the amount of bonding antibodies compared to the first 28 days of injections.

Unlike neutral antibodies to help kill viruses, bonding antibodies will attach to the virus but do not destroy or prevent infection.

A johnson & Johnson vaccine vial at New York vaccination in April. Photo: AP.

In July, J & J announced the temporary data in the first phase of 1 / 2A in the New England Medical Journal, showing that neutral antibodies created by their vaccine remained stable for 8 months after the first dose.

We look forward to discussing with public health officials on a potential strategy for our J & J vaccine, which is an enhanced dose injection after the first dose for 8 months or more, Mathai Mammen, who is in charge of research

Although J & J is a one-dose vaccine, many scientists have stated that those who have injected J & J need to enhance the dose.

J & J said the company is working with the Centers for Disease Control and Prevention (CDC), Department of Food and Drug Administration (FDA), European Pharmaceutical Agency, World Health Organization and many muscles

Some countries, including the US, have begun to promote enhanced doses for vulnerable groups, such as immunocompromised people, when they witness the danger of the Delta transformation.